Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance

British Journal of Clinical Pharmacology

Volumn 81, Issue 6, 2016, Pages 1153-1164

  Knights, Kathleen M ^a   Spencer, Shane M ^a   Fallon, John K ^b   Chau, Nuy ^a   Smith, Philip C ^b   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

human kidney microsomes; microsomal yield; renal drug glucuronidation clearance; UGT1A9; UGT2B7

Indexed keywords

DEFERIPRONE; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; PROPOFOL; XENOBIOTIC AGENT; ZIDOVUDINE; GLUCURONOSYLTRANSFERASE; MORPHINE; PROTEIN; PYRIDONE DERIVATIVE; UDP-GLUCURONOSYLTRANSFERASE 1A9; UDP-GLUCURONOSYLTRANSFERASE, UGT1A6; UGT2B7 PROTEIN, HUMAN;

ARTICLE; DRUG CLEARANCE; DRUG GLUCURONIDATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRINSIC CLEARANCE; KIDNEY MICROSOME; KIDNEY PARENCHYMA; METABOLIC CLEARANCE; MICROSOMAL PROTEIN PER GRAM OF KIDNEY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; RENAL CLEARANCE; ENZYMOLOGY; KIDNEY; LIVER MICROSOME; METABOLISM; MICROSOME;

GLUCURONOSYLTRANSFERASE; KIDNEY; MICROSOMES; MICROSOMES, LIVER; MORPHINE; PROPOFOL; PROTEINS; PYRIDONES; ZIDOVUDINE;

EID: 84960540282     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12889     Document Type: Article

References (58)

1. Gaganis P, Miners JO, Brennan JS, Thomas A, Knights KM,. Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther 2007; 323: 422-30.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO,. S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 2005; 60: 423-33.
3. Rush GF, Hook JB,. Characteristics of renal UDP-glucuronosyltransferase. Life Sci 1984; 35: 145-53.
4. Hjelle JT, Hazelton GA, Klaassen CD, Hjelle JJ,. Glucuronidation and sulfation in rabbit kidney. J Pharmacol Exp Ther 1986; 236: 150-6.
5. Yue Q, Odar-Cederlof I, Svensson JO, Sawe J,. Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol 1988; 63: 337-41.
6. Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Griffith Humphreys W, Boulton DW,. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012; 76: 432-44.
7. Knights KM, Miners JO,. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev 2010; 42: 60-70.
8. Knights KM, Rowland A, Miners JO,. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 2013; 76: 587-602.
9. Bowalgaha K, Miners JO,. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001; 52: 605-9.
10. McGurk KA, Brierley CH, Burchell B,. Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 1998; 55: 1005-12.
11. Mazoit JX, Sandouk P, Scherrmann J-M, Roche A,. Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 1990; 48: 613-8.
12. Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi ]Y, Kunimoto F, Horiuchi R,. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol 2005; 60: 176-82.
13. Soars MG, Burchell B, Riley RJ,. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 2002; 301: 382-90.
14. Al-Jahdari WS, Yamamoto K, Hiraoka H, Nakamura K, Goto F, Horiuchi R,. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver. Eur J Clin Pharmacol 2006; 62: 527-33.
15. Gill KL, Houston JB, Galetin A,. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 2012; 40: 825-35.
16. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A,. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45.
17. Ohno S, Nakajin S,. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2009; 37: 32-40.
18. Court MH, Zhang X, Ding X, Yee KK, Hesse LM, Finel M,. Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 2012; 42: 266-77.
19. Fallon JK, Neubert H, Goosen TC, Smith PC,. Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyltransferase 1 A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring. Drug Metab Dispos 2013; 41: 2076-80.
20. Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC,. Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using nano UPLC-MS/MS with selected reaction monitoring. J Proteome Res 2013; 12: 4402-13.
21. Achour B, Russell MR, Barber J, Rostami-Hodjegan A,. Simultaneous quantification of abundance of several cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos 2014; 42: 500-10.
22. Ohtsuki S, Kawakami H, Inoue T, Nakamura K, Tateno C, Katsukura Y, Obuchi W, Uchida Y, Kamiie J, Horie T, Terasaki T,. Validation of uPA/SCID mouse with humanized liver as a model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS. Drug Metab Dispos 2014; 42: 1039-43.
23. Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK, Glish GL, Smith PC,. Quantification of human uridine-diphosphate glucuronosyltransferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem 2012; 84: 98-105.
24. Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C,. Quantitative profiling of human renal UGTs and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos 2015; 43: 611-5.
25. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, Knights KM,. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT); kinetic studies using human kidney cortical microsomes and recombinant UGT1 A9 and UGT2B7. Biochem Pharmacol 2004; 67: 191-9.
26. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ,. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
27. Phillips AH, Langdon RG,. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 1962; 237: 2652-60.
28. Margoliash E, Frohwirt N,. Spectrum of horse-heart cytochrome c. Biochem J 1959; 71: 570-2.
29. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT,. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 2003; 56: 433-40.
30. Miners JO, Mackenzie PI, Knights KM,. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 2010; 42: 196-208.
31. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO,. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1 a substrates. Pharmacogenet Genomics 2007; 17: 1017-29.
32. Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, Knights KM,. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 2011; 39: 644-52.
33. Rowland A, Knights KM, Mackenzie PI, Miners JO,. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1 A9 substrates but not UGT1A1 and UGT1 A6 activities. Drug Metab Dispos 2008; 36: 1056-62.
34. Boase S, Miners JO,. In vitro-in vivo correlations for drug eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 2002; 54: 493-503.
35. 4 -3-keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6 α- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos 2007; 35: 363-70.
36. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO,. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline), androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 2006; 34: 449-56.
37. Uchaipichat V, Raungrut P, Chau N, Janchawee B, Evans AM, Miners JO,. Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions from ketamine inhibition of codeine and morphine glucuronidation. Drug Metab Dispos 2011; 39: 1324-8.
38. Chau N, Elliot DJ, Lewis BC, Burns K, Johnston MR, Mackenzie PI, Miners JO,. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J Pharmacol Exp Ther 2014; 349: 126-37.
39. Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, Zamek-Gliszczynski MJ,. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos 2014; 42: 182-92.
40. Milne RW, Nation RL, Somogyi AA,. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996; 28: 345-472.
41. Aitio A, Vainio H,. UDP-glucuronosyltransferase and mixed function oxidase activity in microsomes prepared by differential centrifugation and calcium aggregation. Acta Pharmacol Toxicol 1975; 39: 555-61.
42. Bohman S-V,. The ultrastructure of the renal medulla and interstitial cells. In: The renal papilla and hypertension, eds, Mandal AK, Bohman S-V,. New York: Springer Science + Business Media, 1980; 7-33.
43. Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Tetu B, Guillemette C,. Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans. J Pathol 2011; 223: 425-35.
44. Menard V, Levesque E, Chen S, Eap O, Joy MS, Ekstrom L, Rane A, Guillemette C,. Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer. Pharmacogenet Genomics 2013; 23: 684-96.
45. Damkjaer M, Vafee M, Moller ML, Braad PE, Petersen H, Hoilund-Carlsen PF, Bie P,. Renal cortical and medullary blood flow responses to altered NO availability in humans. Am J Physiol Regul Integr Comp Physiol 2010; 299: R1449-55.
46. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T,. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 2008; 36: 1461-4.
47. Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, Chen X, Li L, Wu S, Chen Y, Jiang H, Tan L, Xie J, Zhu X, Liang S, Deng H,. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin 2008; 40: 426-36.
48. Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, Guillemette C,. Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential. Drug Metab Dispos 2015; 43: 1331-5.
49. Aueviriyavit S, Furihata T, Morimoto K, Kobayashi K, Chiba K,. Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in interindividual variability in the expression of UGT1A6 and UGT1A9 but not UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers. Drug Metab Pharmacokinet 2007; 22: 391-8.
50. Foti RS, Fisher MB,. UDP-glucuronosyltransferases: Pharmacogenetics, functional characterization, and clinical relevance. In: Encyclopedia of Drug Metabolism and Interactions, eds, Lyubimov A, Rodrigues AD, Sinz M,. New Jersey: John Wiley & Sons, 2012; 1-71.
51. Hui DG, Meech R, McKinnon RA, Mackenzie PI,. Transcriptional regulation of UDP-glucuronosyltransferase genes. Drug Metab Rev 2014; 46: 421-58.
52. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO,. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 2007; 321: 137-47.
53. max values of UGT1A9. Drug Metab Dispos 2011; 39: 2117-29.
54. Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, Goosen TC,. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 2012; 40: 1051-65.
55. Takizawa D, Hiraoka H, Nakamura K, Yamamoto K, Horiuchi R,. Propofol concentrations during the anhepatic phase of living-related donor liver transplantation. Clin Pharmacol Ther 2004; 76: 648-9.
56. Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A,. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 2009; 37: 82-9.
57. Zhang H, Patana A-S, Mackenzie PI, Ikushiro S, Goldman A, Finel M,. Human UDP-glucuronosyltransferase expression in insect cells: ratio of active to inactive recombinant proteins and the effects of a C-terminal his-tag on glucuronidation kinetics. Drug Metab Dispos 2012; 40: 1935-44.
58. Zientek MA, Youdim K,. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug metabolizing enzymes. Drug Metab Dispos 2015; 43: 163-81.